Additional file 2: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Figure S2. Proportion with EDSS progression at each year in the placebo/delayed treatment and IFN β-1a 44 μg SC tiw groups by ≥4 versus 0 active T2 lesions at 6 months. (PDF 189 kb

Additional file 5: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Figure S4. Proportion relapsed at each year by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 269 kb

Additional file 3: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Table S1. (a) Performance of T2 lesions on predicting EDSS progression at Year 2 and Year 4. (b) Performance of T2 lesions on predicting relapse at Year 2 and Year 4. (DOCX 15 kb

Additional file 1: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Figure S1. Proportion with EDSS progression at each year by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 258 kb

Additional file 7: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Figure S6. Proportion relapsed at each year by ≥2 versus 0–1 active T2 lesions at 12 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 273 kb

Additional file 4: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Figure S3. Time to sustained EDSS progression by ≥2 versus 0–1 active T2 lesions at 6 months. (a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group. (PDF 229 kb

Supplementary Material, Supplementary_files_final_version_PREFERMS – Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial

<p>Supplementary Material, Supplementary_files_final_version_PREFERMS for Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial by Bruce A.C. Cree, Douglas L. Arnold, Mark Cascione, Edward J. Fox, Ian M. Williams, Xiangyi Meng, Lesley Schofield and Nadia Tenenbaum in Therapeutic Advances in Neurological Disorders</p